1. Home
  2. COPR vs BOLD Comparison

COPR vs BOLD Comparison

Compare COPR & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

COPR

Idaho Copper Corporation Common Stock

N/A

Current Price

$2.21

Market Cap

54.0M

Sector

N/A

ML Signal

N/A

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$2.52

Market Cap

57.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
COPR
BOLD
Founded
N/A
2018
Country
United States
Employees
32
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
54.0M
57.5M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
COPR
BOLD
Price
$2.21
$2.52
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.00
AVG Volume (30 Days)
34.2K
194.0K
Earning Date
N/A
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
32.47
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.16
$0.96
52 Week High
$4.16
$2.79

Technical Indicators

Market Signals
Indicator
COPR
BOLD
Relative Strength Index (RSI) 8.29 62.33
Support Level N/A $2.35
Resistance Level $3.00 $2.64
Average True Range (ATR) 0.31 0.10
MACD -0.07 -0.04
Stochastic Oscillator 0.00 45.61

Price Performance

Historical Comparison
COPR
BOLD

About COPR Idaho Copper Corporation Common Stock

Idaho Copper Corp is a USA-based company focused on exploring and developing its copper-molybdenum-silver deposit in Idaho, known as the CuMo project. The CuMo project currently consists of several federal unpatented lode mining claims and various patented mining claims. The unpatented lode mining claims and patented claims are situated in an unorganized mining district, in Boise County, Idaho, spanning Sections in Township 7N and 8N, Range 5E and 6E, Boise Meridian.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: